患者报告结局作为脑肿瘤患者总生存与无进展生存的预后指标:随机临床试验的系统综述与荟萃分析
该系统综述与荟萃分析依据PRISMA 2020,纳入8项随机对照试验共6846例胶质瘤患者,评估基线EORTC QLQ-C30与QLQ-BN-20各领域评分与总生存(OS)及无进展生存(PFS)的关联。结果显示基线认知功能与躯体功能较高与OS改善相关,功能领域汇总亦呈保护性关联,BN-20领域与OS无关联。
要点
- 基线认知功能每升高10分与OS改善相关(HR=0.94,95%CI 0.91–0.97)。
- 基线躯体功能每升高10分与OS相关(HR=0.97,95%CI 0.94–1.00)。
- 功能与认知PRO领域有望成为胶质瘤试验的稳健预后标志物。
核心结论
- 功能与认知PRO领域可能是胶质瘤试验中稳健的生存预后标志物。
- 研究结果支持PRO与临床、影像及分子指标互补使用。
- 支持将PRO整合进未来神经肿瘤试验的疗效评估选择。
研究设计与样本
- 遵循PRISMA 2020指南的系统综述与荟萃分析。
- 纳入报告基线EORTC QLQ-C30或QLQ-BN-20 PRO及相应生存结局的随机对照试验。
- 共纳入8项试验、6846例患者。
- 提取每个PRO领域每增加10分对应的风险比(HR)。
- 采用随机效应模型生成合并HR,并评估异质性、ROB 2偏倚风险与GRADE证据确定性。
主要发现
- 较高基线认知功能与OS改善显著相关(HR=0.94,95%CI 0.91–0.97)。
- 较高基线躯体功能与OS相关(HR=0.97,95%CI 0.94–1.00)。
- 功能领域汇总呈保护性关联(HR=0.96,95%CI 0.93–1.00)。
- BN-20领域与总生存无关联。
- 报告EORTC QLQ-C30量表的汇总分析与PFS改善相关(HR=0.99,95%CI 0.99–0.99)。
关键数值与推荐
- 认知功能每增加10分:OS的HR=0.94(95%CI 0.91–0.97)。
- 躯体功能每增加10分:OS的HR=0.97(95%CI 0.94–1.00)。
- 功能领域汇总:OS的HR=0.96(95%CI 0.93–1.00)。
- EORTC QLQ-C30量表汇总:PFS的HR=0.99(95%CI 0.99–0.99)。
- 躯体功能:PFS的HR=0.99(95%CI 0.97–1.0);所有功能量表汇总:PFS的HR=0.99(95%CI 0.99–0.99)。
临床怎么用
- 在胶质瘤患者的预后评估中,可结合基线认知与躯体功能PRO评分补充临床、影像与分子指标。
- 在神经肿瘤临床试验设计时,可考虑将PRO纳入疗效评估与终点选择。
局限性
- 异质性、偏倚风险(ROB 2)与证据确定性(GRADE)均已评估,但摘要未报告具体结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient-reported outcomes (PROs) are increasingly recognized as essential endpoints in neuro-oncology, yet their prognostic value for survival across brain tumor trials remains incompletely defined. We conducted a systematic review and meta-analysis to quantify the association between key PRO domains and overall survival (OS) and progression-free survival (PFS)in patients with glioma. METHODS: Following PRISMA 2020 guidelines, we included randomized controlled trials that reported baseline PROs using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 or European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Neoplasm-20 questionnaires, with corresponding survival outcomes. Hazard ratios (HRs) per 10-point increase in each PRO domain were extracted. Random-effects models generated pooled HRs. Heterogeneity, risk of bias (ROB 2), and certainty of evidence (GRADE) were assessed. RESULTS: Eight trials comprising 6,846 patients were included. Higher baseline cognitive functioning was significantly associated with improved OS (HR = 0.94, 95% CI [0.91–0.97]), as was physical functioning (HR = 0.97, 95% CI [0.94-1.00]). Pooled functional domains showed a protective association (HR = 0.96, 95% CI [0.93-1.00]), while BN-20 domains showed no association with overall survival. Pooled analysis of studies reporting EORTC QLQ-C30 scales was associated with improved PFS (HR = 0.99, 95% CI [0.99–0.99]). Subgroup analysis of physical functioning showed an association with improved PFS (HR = 0.99, 95% CI [0.97-1.0]), and the pooled analysis of all functional scales showed the same direction (HR = 0.99, 95% CI [0.99–0.99]). CONCLUSIONS: Functional and cognitive PRO domains appear to have potential to be robust prognostic markers of survival in glioma trials, and these findings support the complementary role of PROs alongside clinical, radiographic, and molecular measures. Our findings support integrating PROs into response assessment selection in future neuro-oncology trials.
引用
- Sanikommu S, Santos AN, Wipplinger C, et al. Patient-reported outcomes as prognostic indicators for overall survival and progression-free survival in brain tumor patients - a systematic review and meta-analysis of randomized clinical trials. J Neurooncol. 2026. PMID: 41491296. doi:10.1007/s11060-025-05419-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。